Physician profile
Vimala D Ravi
NPI 1811437296
$5,641.11
in general payments reported to CMS, 2019-2025
30 companies · $945 in 2025
The $945 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,165 · 2022: $722 · 2023: $910 · 2024: $1,899 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,549 · Travel and Lodging: $1,186 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,548.66 |
| Travel and Lodging | $1,185.55 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,185.55 | 2024 | |
| Novo Nordisk INC | $883.77 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $702.86 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $623.98 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $530.15 | 2021-2025 | |
| Lilly USA, LLC | $397.85 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $197.51 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $122.64 | 2021-2022 | |
| Inari Medical, INC. | $107.05 | 2021 | |
| Pfizer INC. | $105.27 | 2023 | |
| Shield Therapeutics INC | $98.74 | 2023-2025 | Accrufer |
| Abbott Laboratories | $96.48 | 2021-2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $80.44 | 2021-2025 | Veozah |
| Merck Sharp & Dohme LLC | $57.57 | 2021 | |
| Glaxosmithkline, LLC. | $52.78 | 2021-2023 | Arexvy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $47.41 | 2021-2022 | |
| Si-Bone, INC. | $45.97 | 2021 | |
| Esperion Therapeutics, INC. | $42.95 | 2025 | Nexletol |
| Exact Sciences Corporation | $37.95 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $33.62 | 2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $31.51 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.61 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.30 | 2025 | Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $22.29 | 2023 | Perseris |
| Sumitomo Pharma America, INC. | $16.94 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $16.46 | 2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.75 | 2021 | |
| Althera Pharmaceuticals LLC | $15.36 | 2022 | |
| Vistapharm, INC. | $14.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vimala Ravi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.